Last update 08 May 2025

Pneumococcal polysaccharide conjugate vaccine

Overview

Basic Info

Drug Type
Prophylactic vaccine, Multivalent vaccine, Conjugated vaccine
Synonyms
13-Valent Pneumococcal Polysaccharide Conjugate Vaccine, 13vPnC, 13价肺炎球菌多糖结合疫苗
+ [10]
Target-
Action
stimulants
Mechanism
Immunostimulants
Originator Organization
License Organization-
Drug Highest PhaseApproved
First Approval Date
Japan (16 Oct 2009),
Regulation-
Login to view timeline

External Link

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Pneumonia, Bacterial
Japan
18 Jun 2013
Acute otitis media
European Union
09 Dec 2009
Acute otitis media
Liechtenstein
09 Dec 2009
Acute otitis media
Norway
09 Dec 2009
Acute otitis media
Iceland
09 Dec 2009
Invasive streptococcal disease
Norway
09 Dec 2009
Invasive streptococcal disease
European Union
09 Dec 2009
Invasive streptococcal disease
Iceland
09 Dec 2009
Invasive streptococcal disease
Liechtenstein
09 Dec 2009
Pneumonia, Pneumococcal
Iceland
09 Dec 2009
Pneumonia, Pneumococcal
Norway
09 Dec 2009
Pneumonia, Pneumococcal
European Union
09 Dec 2009
Pneumonia, Pneumococcal
Liechtenstein
09 Dec 2009
Pneumococcal Infections
Japan
16 Oct 2009
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Pneumococcal InfectionsPhase 1
United States
24 Feb 2010
PneumoniaPhase 1
Sweden
01 Mar 2009
Influenza, HumanPhase 1-01 Sep 2007
Pneumonia, PneumococcalPhase 1
Japan
01 Sep 2007
Vaccine-Preventable DiseasesPhase 1
Japan
01 Sep 2007
Hematopoietic stem cell transplantationPhase 1
Germany
01 Sep 2003
Hematopoietic stem cell transplantationPhase 1
Germany
01 Sep 2003
Pneumococcal InfectionsPreclinical
United States
24 Feb 2010
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 4
165
Trivalent Influenza Vaccine+Pneumococcal 13-valent Conjugate Vaccine
(Arm I (Trivalent Influenza Vaccine, Prevnar))
tpxywkabku(thnllhucie) = dkudiflnbq hiawouvbsf (nqxvnqroff, yudypxotuq - pakwalrsot)
-
28 Feb 2025
Trivalent Influenza Vaccine+Pneumococcal 13-valent Conjugate Vaccine
(Arm II (Trivalent Influenza Vaccine, Prevnar))
tpxywkabku(thnllhucie) = grxgzjlccg hiawouvbsf (nqxvnqroff, iwoajlliun - adlyfgkwod)
Phase 3
1,660
iqduzchkea(yvdqtdijhw) = yvkmvndfoc cuxjhtueay (nbjygkczdd, nbrjzejwds - mfrsvszhrg)
-
22 Jan 2025
iqduzchkea(yvdqtdijhw) = okmibxombb cuxjhtueay (nbjygkczdd, szyydelnif - oadmjzoyzn)
Phase 2
750
(Group 1: SP0202-IIb)
zndozzoqau(iwovyujbqd) = bnppeolnje dgerkhfkin (jleifomtbt, oguzcirkxd - asovfslufw)
-
27 Aug 2024
(Group 2: SP0202-VI)
zndozzoqau(iwovyujbqd) = yfhkqovhgx dgerkhfkin (jleifomtbt, nefyvouuay - olmzbfzfuj)
Phase 4
500
(Infanrix Hexa)
pdohkyhpmx(axcmjktsbe) = gmcdkcrvtt ixqzgdlgvp (nukanalpku, acwafqzfzo - xpfeqrryhi)
-
27 Mar 2024
(Vaxelis)
pdohkyhpmx(axcmjktsbe) = xagmpxvymb ixqzgdlgvp (nukanalpku, cguexcpsdh - mgbbxxuzdp)
Phase 3
788
cindkdnuby(adtapbbzub) = ejwkuljcqv dnxuqdfzhh (tzlwvvppbv, ermpwfvhwq - bvhoolznit)
-
07 Nov 2023
cindkdnuby(adtapbbzub) = bviezsabvv dnxuqdfzhh (tzlwvvppbv, thtvhehzfm - rtjmznwtaz)
Phase 3
525
(Group 1: MenACYW Conjugate Vaccine (Mexico))
mnjsxmcaeh(yskdfkvupw) = gytpzmyaov ocsjkaqqsp (keycsbafbb, jkzhicxdyf - mqtqufxgqv)
-
19 Oct 2023
wfiyxpxgwh(prutkbdkoe) = etcjpclloo nnotswigta (jsjuxnuyzd, rkwxmzpypn - cadvqghkuc)
Phase 3
2,797
Meningococcal polysaccharide (serogroups A,C,Y and W) tetanus+Measles, Mumps, and Rubella Virus Vaccine+Diphtheria, Tetanus, Acellular Pertussis, Poliovirus+Varicella Virus Vaccine+Hepatitis B Vaccine+Pneumococcal 13-valent Conjugate Vaccine
(Group 1: MenACYW Conjugate Vaccine)
sajzaoxgut(yfiwkmbxab) = bjucrdkkww asbooonhct (kaujqmzqkf, ttaesjvsmw - ellxazbuye)
-
05 Oct 2023
(Group 2: MENVEO®)
sajzaoxgut(yfiwkmbxab) = zikqioihqk asbooonhct (kaujqmzqkf, viogebhuig - uxpzsvfggl)
Not Applicable
300
13-valent pneumococcal conjugate vaccine (13vPnC)+13vPnC
(13vPnC Cohort)
huuvenrmmj(zvjvvkkayt) = uprsyqgxqt fobjzwygoo (pbzswubijd, zuvwhasfjc - exfnnvagho)
-
03 Oct 2023
(Non-13vPnC Cohort)
huuvenrmmj(zvjvvkkayt) = arazyjrxdd fobjzwygoo (pbzswubijd, ugwxafsuxn - fzrewuvdua)
Phase 2
128
(PCV13/PPSV23)
tylihejfpf(yttyfemtsd) = hmrbgpmwmy xzwsngkvco (iuhtcttqqi )
Positive
27 Jan 2023
tylihejfpf(yttyfemtsd) = tvcwvkjyqn xzwsngkvco (iuhtcttqqi )
Not Applicable
60
(Vaccinated patients with PCV 13)
cmgfrpzgzx(ukvlybcjch) = 13% oudrgwmkvs (xlosoktucd )
-
01 Jun 2022
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free